Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2014; 20(45): 17141-17147
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17141
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17141
Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus
Jia-Zhou Ye, Tao Bai, Liang Ma, Bang-De Xiang, Le-Qun Li, Department of Hepatobiliary and Pancreas Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Yong-Quan Zhang, Hai-Hong Ye, Department of Hepatobiliary and Pancreas Surgery, Affiliated Minzu Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Author contributions: Ye JZ and Zhang YQ contributed equally to this work; Ye JZ, Zhang YQ, Ye HH, Bai T, Ma L, Xiang BD and Li LQ designed and performed the research; Ye JZ and Bai T contributed new reagents/analytical tools; Ma L and Xiang BD analyzed the data; and Ye JZ wrote the paper.
Correspondence to: Le-Qun Li, MD, PhD, Professor, Department of Hepatobiliary and Pancreas Surgery, Affiliated Tumor Hospital of Guangxi Medical University, No. 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. lequnlicn@126.com
Telephone: +86-771-3112167 Fax: +86-771-3900863
Received: February 26, 2014
Revised: May 22, 2014
Accepted: July 22, 2014
Published online: December 7, 2014
Processing time: 287 Days and 8.6 Hours
Revised: May 22, 2014
Accepted: July 22, 2014
Published online: December 7, 2014
Processing time: 287 Days and 8.6 Hours
Core Tip
Core tip: Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is generally considered to be related to or an absolute contraindication for hepatic resection or adjuvant chemotherapeutic methods such as transarterial chemoembolization (TACE). Only conservative and palliative treatments are available. However, many experts have indicated that surgery or TACE prolongs survival and lowers recurrence compared to palliative treatments. Thus, treatments of HCC with PVTT remain controversial. Our study explored appropriate treatment strategies and identified prognostic factors by comparing the survival periods and rates for HCC-PVTT patients with 4 kinds of treatments.